Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Iovance Biotherapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
IOVA
Nasdaq
2836
www.iovance.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics Targets 2027 Lung Cancer Filing as AMTAGVI Sales Climb
- Nov 16th, 2026 8:14 am
SLS, IBRX And IOVA Join Merck And Lilly On BlackRock’s Q3 Buy List — A Vanguard Unit Adds All Of Them Too
- Nov 16th, 2026 12:31 am
Cellectis SA (CLLS) (Q3 2026) Earnings Call Highlights: Strategic Shift to Gene Editing ...
- Nov 13th, 2026 4:03 pm
Iovance Biotherapeutics to Present at Upcoming Conference
- Nov 12th, 2026 2:05 pm
CAPR vs IBRX vs SLS vs IOVA: Whose Insiders Cashed Out The Most — And Who Bought Before A 5X Surge?
- Nov 11th, 2026 11:04 pm
Barclays, Deutsche Bank Reveal Stakes In Retail-Favorite Cancer Stocks SLS, IBRX And IOVA — Geode Adds More
- Nov 9th, 2026 1:33 am
Iovance Biotherapeutics (IOVA) Q3 Earnings Sharpen Focus On Margin Recovery
- Nov 6th, 2026 11:13 pm
IOVA Q3 Earnings Beat on Amtagvi Sales and Lower R&D Costs
- Nov 6th, 2026 5:31 am
Iovance Biotherapeutics Inc (IOVA) (Q3 2026) Earnings Call Highlights: Record $122 Million ...
- Nov 6th, 2026 4:10 am
IOVA Q3 Earnings Call Highlights Amtagvi Growth and Pipeline Progress
- Nov 6th, 2026 3:23 am
Iovance Biotherapeutics (IOVA) Lifileucel Wins Fast Track After Strong Sarcoma Trial Data
- Nov 5th, 2026 3:16 pm
Iovance (IOVA) Q3 2026 Earnings Call Transcript
- Nov 5th, 2026 2:34 pm
Iovance Biotherapeutics Q3 Earnings Call Highlights
- Nov 5th, 2026 2:14 pm
Iovance Biotherapeutics (IOVA) Reports Q3 Loss, Beats Revenue Estimates
- Nov 5th, 2026 5:15 am
Iovance Biotherapeutics: Q3 Earnings Snapshot
- Nov 5th, 2026 5:10 am
Iovance Biotherapeutics Reports Record Third Quarter 2026 Revenue of ~$122M, Business Achievements, and Corporate Updates
- Nov 5th, 2026 5:00 am
AMRX Q3 Earnings & Sales Beat Estimates, FY'26 Guidance Raised
- Nov 4th, 2026 7:02 am
NVO Q3 Earnings Beat Estimates on Wegovy Pill Growth, Outlook Raised
- Nov 4th, 2026 6:35 am
Harmony Biosciences Holdings, Inc. (HRMY) Q3 Earnings and Revenues Lag Estimates
- Nov 4th, 2026 5:55 am
Recursion's Q3 Earnings Beat Estimates on Sanofi Milestone Revenues
- Nov 3rd, 2026 7:59 am
Scroll